1. Grin-Jorgenson CM, Rigel DS, Friedman RJ: The worldwide incidence of malignant melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S (eds) Cutaneous Melanoma. Lippincott, Philadelphia, 1992, pp 28–45
2. Kish JA, Kopecky K, Samson MK, Von Hoff DD, Fletcher WS, Kempf RA, Muggia FM: Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group Study. Invest N Drugs 9:105–108, 1991
3. Cohen SM, Ohnuma T, Cheung T, Holland JF: Bleomycin, carmustine, vincristine, and dacarbazine in patients with metastatic melanoma. Cancer Treat Rep 67:947–948, 1983
4. Luikart SK, Kennealey GT, Kirkwood JM: Randomized phase II trial of vinblastine, bleomycin, and cisdichlorodiammineplatinum versus dacarbazine in malignant melanoma. J Clin Oncol 2:164, 1984
5. Mitchell MS, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Boswell WD, Dean G, Stevenson L: Active-specific immunotherapy for melanoma. J Clin Oncol 8:856–869, 1990